AstraZeneca bets AAV gene therapy will still deliver the goods

WASHINGTON — It’s two weeks until Congress leaves town in August, and a prominent House panel is throwing a wrench in what seemed like a smooth path forward for legislation to require more transparency in health care prices, and to change Medicare drug payments.

The House Energy & Commerce Committee already introduced, held multiple hearings on, and unanimously passed out of committee a package of legislation including transparency requirements for hospitals and pharmacy benefit managers and a so-called “site-neutral” pay policy for drugs administered in doctors’ offices.

advertisement

But leaders of the House Ways & Means Committee are planning to release their own health care legislation this month, complicating the chamber’s path to passing something soon, four lobbyists told STAT.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!